Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 16759048)

1.

Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial.

De Luca A, Di Giambenedetto S, Cingolani A, Bacarelli A, Ammassari A, Cauda R.

Antivir Ther. 2006;11(3):321-7.

PMID:
16759048
2.

When can HIV clinical trials detect treatment effects on drug resistance?

Hill AM, Moecklinghoff C, DeMasi R.

Int J STD AIDS. 2015 Mar;26(4):268-78. doi: 10.1177/0956462414536885. Epub 2014 May 29. Review.

PMID:
24874537
3.

[Analysis of HIV genotypic drug resistance among pediatric HIV/AIDS cases with virological failure after free antiretroviral therapy in Yunnan province].

Zhong M, Yang S, Yang B, Liu J, Li J, Lou J, Li H.

Zhonghua Yi Xue Za Zhi. 2014 Apr 1;94(12):884-8. Chinese.

PMID:
24854905
4.

An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers R, Alvarez-Uria G, Streinu-Cercel A, Ene L, Wensing A, Reiss P, van Sighem AI, Nelson M, Emery S, Montaner JS, Lane HC, Larder BA; RDI Study Group.

J Antimicrob Chemother. 2014 Apr;69(4):1104-10. doi: 10.1093/jac/dkt447. Epub 2013 Nov 24.

5.

Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda.

Rusine J, Asiimwe-Kateera B, van de Wijgert J, Boer KR, Mukantwali E, Karita E, Gasengayire A, Jurriaans S, de Jong M, Ondoa P.

PLoS One. 2013 Aug 12;8(8):e64345. doi: 10.1371/journal.pone.0064345. eCollection 2013.

6.

Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study.

Ribeiro KM, Biscione FM, Westin MR, Machado DP, Greco DB, Tupinambás U.

Braz J Infect Dis. 2014 Jan-Feb;18(1):1-7. doi: 10.1016/j.bjid.2013.04.001. Epub 2013 Jul 31.

7.

Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.

Al Hajjar SH, Frayha H, Althawadi S.

Ann Saudi Med. 2012 Nov-Dec;32(6):565-9. doi: 10.5144/0256-4947.2012.565.

PMID:
23396017
8.

Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.

Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, Koulla-Shiro S, Delaporte E, Mpoudi-Ngole E, Peeters M.

J Int AIDS Soc. 2013 Jan 31;16:18004. doi: 10.7448/IAS.16.1.18004.

9.

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

Passaes CP, Guimarães ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, Morgado MG.

J Med Virol. 2012 Dec;84(12):1869-75. doi: 10.1002/jmv.23409.

PMID:
23080489
10.

Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Niubó J, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR Study Team.

Antivir Ther. 2012;17(3):577-83. doi: 10.3851/IMP2025. Epub 2011 Dec 19. Erratum in: Antivir Ther. 2012;17(3):597.

PMID:
22301439
11.

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AI, Schuurman R, Wensing AM.

Antivir Ther. 2012;17(2):377-86. doi: 10.3851/IMP2010. Epub 2011 Dec 2.

PMID:
22297391
12.

Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.

Ortu M, Vitiello P, Adorni F, Rossotti R, Di Vincenzo P, Vigano O, Galli M, Rusconi S.

Curr HIV Res. 2011 Dec 1;9(8):625-9.

PMID:
22211659
13.

It is time to consider third-line options in antiretroviral-experienced paediatric patients?

Zyl GU, Rabie H, Nuttall JJ, Cotton MF.

J Int AIDS Soc. 2011 Nov 15;14:55. doi: 10.1186/1758-2652-14-55.

14.

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.

Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby M.

Antivir Ther. 2011;16(3):395-404. doi: 10.3851/IMP1759.

PMID:
21555822
15.

Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.

Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, Bélec L, Si-Mohamed A, Weiss L.

Scand J Infect Dis. 2011 May;43(5):373-9. doi: 10.3109/00365548.2011.552520. Epub 2011 Feb 22.

PMID:
21341978
16.

Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group.

J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927.

PMID:
20981785
17.

Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites.

Ruan Y, Xing H, Wang X, Tang H, Wang Z, Liu H, Su B, Wu J, Li H, Liao L, Li J, Wu JW, Shao Y.

Trop Med Int Health. 2010 Nov;15(11):1357-63. doi: 10.1111/j.1365-3156.2010.02621.x. Epub 2010 Sep 25.

18.

Adherence to antiretroviral therapy, virological response, and time to resistance in the Dakar cohort.

Tournoud M, Etard JF, Ecochard R, DeGruttola V.

Stat Med. 2010 Jan 15;29(1):14-32. doi: 10.1002/sim.3779.

19.

Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.

Lorenzen T, Walther I, Stoehr A, Salzberger B, Plettenberg A; Radata Study Group.

Infection. 2009 Dec;37(6):528-33. doi: 10.1007/s15010-009-9022-6. Epub 2009 Oct 13.

PMID:
19826762
20.

Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study.

Bracciale L, Fanti I, Di Giambenedetto S, Colafigli M, Prosperi M, Bacarelli A, Santangelo R, Cattani P, Cauda R, De Luca A.

J Clin Virol. 2009 Nov;46(3):290-4. doi: 10.1016/j.jcv.2009.07.013. Epub 2009 Aug 21.

PMID:
19699675
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk